Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,128,415
  • Shares Outstanding, K 145,790
  • Annual Sales, $ 4,110 K
  • Annual Income, $ -119,360 K
  • 60-Month Beta 0.77
  • Price/Sales 266.62
  • Price/Cash Flow N/A
  • Price/Book 141.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.23
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.29
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +23.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.13 +50.88%
on 03/16/20
19.36 -60.02%
on 03/09/20
+0.29 (+3.89%)
since 03/03/20
3-Month
2.95 +162.37%
on 01/06/20
19.36 -60.02%
on 03/09/20
+4.76 (+159.73%)
since 01/03/20
52-Week
1.91 +304.18%
on 10/02/19
19.36 -60.02%
on 03/09/20
+3.88 (+100.52%)
since 04/03/19

Most Recent Stories

More News
Kessler Topaz Meltzer & Check, LLP Reminds Inovio Pharmaceuticals, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio") investors that a securities fraud class action lawsuit has been filed in the United States...

INO : 7.74 (+2.93%)
Inovio Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Inovio Pharmaceuticals, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - April 4, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio" or the "Company")...

INO : 7.74 (+2.93%)
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

AAN : 18.62 (-2.87%)
FLR : 5.98 (-3.55%)
INO : 7.74 (+2.93%)
MGPI : 26.56 (-3.94%)
Shareholder Alert: Robbins LLP Reminds Investors Inovio Pharmaceuticals, Inc. (INO) Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) filed a class action complaint against the Company for alleged violations of the...

INO : 7.74 (+2.93%)
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

ALGN : 154.20 (+1.40%)
INO : 7.74 (+2.93%)
TLRY : 5.54 (-9.18%)
WWE : 34.13 (-1.50%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

INO : 7.74 (+2.93%)
SHAREHOLDER ALERT: Inovio Pharmaceuticals, Inc. Officers and Directors Under Investigation for Allegedly Misleading Statements Concerning COVID-19 Vaccine

Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio" or the "Company"), related to allegedly misleading...

INO : 7.74 (+2.93%)
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AAN, BDX, FLR and INO

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

AAN : 18.62 (-2.87%)
BDX : 226.73 (-2.81%)
FLR : 5.98 (-3.55%)
INO : 7.74 (+2.93%)
INOVIO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Inovio Pharmaceuticals, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - March 31, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ:...

INO : 7.74 (+2.93%)
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

AAN : 18.62 (-2.87%)
FLR : 5.98 (-3.55%)
INO : 7.74 (+2.93%)
MGPI : 26.56 (-3.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade INO with:

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

2nd Resistance Point 8.34
1st Resistance Point 8.04
Last Price 7.74
1st Support Level 7.34
2nd Support Level 6.94

See More

52-Week High 19.36
Fibonacci 61.8% 12.70
Fibonacci 50% 10.64
Fibonacci 38.2% 8.58
Last Price 7.74
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar